These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9607056)

  • 1. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age.
    King JC; Vink PE; Chang I; Kimura A; Parks M; Smilie M; Lichenstein R; Farley JJ
    Vaccine; 1998 Feb; 16(4):361-5. PubMed ID: 9607056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection.
    King JC; Vink PE; Farley JJ; Smilie M; Parks M; Lichenstein R
    Pediatrics; 1997 Apr; 99(4):575-80. PubMed ID: 9093301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.
    King JC; Vink PE; Farley JJ; Parks M; Smilie M; Madore D; Lichenstein R; Malinoski F
    Pediatr Infect Dis J; 1996 Mar; 15(3):192-6. PubMed ID: 8852905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.
    Trück J; Jawad S; Goldblatt D; Roalfe L; Snape MD; Voysey M; Pollard AJ
    Pediatr Infect Dis J; 2016 Jul; 35(7):787-93. PubMed ID: 27088583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
    Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.
    Madhi SA; Izu A; Violari A; Cotton MF; Panchia R; Dobbels E; Sewraj P; van Niekerk N; Jean-Philippe P; Adrian PV;
    Vaccine; 2013 Jan; 31(5):777-83. PubMed ID: 23228814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial.
    Ahmed F; Steinhoff MC; Rodriguez-Barradas MC; Hamilton RG; Musher DM; Nelson KE
    J Infect Dis; 1996 Jan; 173(1):83-90. PubMed ID: 8537687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
    Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.
    Nachman S; Kim S; King J; Abrams EJ; Margolis D; Petru A; Shearer W; Smith E; Moye J; Blanchard S; Hawkins E; Bouquin P; Vink P; Benson M; Estep S; Malinoski F;
    Pediatrics; 2003 Jul; 112(1 Pt 1):66-73. PubMed ID: 12837869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of HIV-exposure and timing of antiretroviral treatment initiation in children living with HIV on antibody persistence and memory responses to Haemophilus influenzae type b and pneumococcal polysaccharide-protein conjugate vaccines.
    Madhi SA; Izu A; Violari A; Cotton MF; Jean-Philippe P; Otwombe K; Adrian PV;
    Vaccine; 2020 Mar; 38(12):2651-2659. PubMed ID: 32070681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.
    Madhi SA; Violari A; Klugman KP; Lin G; McIntyre JA; von Gottberg A; Jean-Philippe P; Cotton MF; Adrian P;
    Vaccine; 2011 Sep; 29(40):6994-7001. PubMed ID: 21787822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.
    Rennels MB; Edwards KM; Keyserling HL; Reisinger KS; Hogerman DA; Madore DV; Chang I; Paradiso PR; Malinoski FJ; Kimura A
    Pediatrics; 1998 Apr; 101(4 Pt 1):604-11. PubMed ID: 9521941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
    Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
    Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers.
    Blum MD; Dagan R; Mendelman PM; Pinsk V; Giordani M; Li S; Bohidar N; McNeely TB
    Vaccine; 2000 May; 18(22):2359-67. PubMed ID: 10738092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.
    Madhi SA; Cohen C; von Gottberg A
    Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants.
    Ahman H; Käyhty H; Tamminen P; Vuorela A; Malinoski F; Eskola J
    Pediatr Infect Dis J; 1996 Feb; 15(2):134-9. PubMed ID: 8822286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana.
    Uffman EA; Li SH; Chen JL; Allen N; Boiditswe S; Fouda GG; Hurst JH; Patel MZ; Steenhoff AP; Cunningham CK; Qin E; Davenport CA; Kelly MS
    Vaccine; 2022 Aug; 40(33):4764-4771. PubMed ID: 35773120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
    Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of humoral response to heptavalent pneumococcal conjugate vaccine in HIV-infected children.
    Costa Ide C; Guilardi F; Kmiliauskis MA; Arslanian C; Baldacci ER
    Rev Saude Publica; 2008 Oct; 42(5):844-50. PubMed ID: 18797574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.